cohen newjersey perinatal 2018.v2.ppt - partnershipmch.org · • commonly employed antimanic...
TRANSCRIPT
10/26/2018
1
Lee S. Cohen, MD
Director, Ammon‐Pinizzotto Center for Women’s Mental HealthMassachusetts General Hospital
Edmund and Carroll Carpenter Professor of Psychiatry
Harvard Medical School
Presented at Maternal and Perinatal Safety Conference . November 1 2018 , Newark, NJ
Course and Treatment of Mood Disorders during Pregnancy and the Postpartum Period : Lessons Learned Across Two Decades
2
Are pregnant women protectedagainst relapse or new onset ofmajor depression?
Major Depression During Pregnancy
O’Hara et al. J Abnorm Psychol. 1990Evans et al. BMJ. 2001Yonkers et al. Epidemiology 2011Roca et al. J Affective Disorders 2013
3
Time to Relapse in Patients Who Maintained or Discontinued Antidepressant
Cohen LS, et al. JAMA. 2006
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 12 24 36
Gestational Age
Percentage of Patients Remaining Well
Maintained (N = 82)
Discontinued (N = 65)
10/26/2018
2
4
Relapse of Bipolar Disorder During Pregnancy
Viguera et al. Am J Psychiatry 2007
Womensmentalhealth.org
5
6
• Medications used when risk to mother and fetus from disorder outweighs risks of pharmacotherapy
• Optimum risk/benefit decision for psychiatrically ill pregnant women
• Patients with similar illness histories make different decisions regarding treatment during pregnancy
• No decision is risk‐free
• Collaborative, patient‐centered approach required
Psychotropic Drug Use in Pregnancy
Henshaw Fam Plann Perspect. 1998
10/26/2018
3
7
• Focus of concern regarding known and unknown risks of fetal exposure to psychiatric medications is increasingly balanced by data supporting risk of exposure to disorder, stress and HPA‐axis dysregulation on fetoplacental unit
• Enhanced appreciation for impact of disorder and chronic stress on long term behavioral outcomes
Treatment of Depression During Pregnancy: Lessons Learned and New Directions
Dysregulation of the HPA Axis
Maternal Stress or Depression
Elevated CRHElevated
Cortisol Levels
IN UTERO
Programming ofFetal HPA Axis
Dysregulation of HPA Axis
Increased Reactivity to Stress
Increased Vulnerability to Mood
and Anxiety Disorders
9
• Some data support increased rates of obstetrical complications and poor neonatal outcome in depressed or anxious pregnant women
• Increased risk of preterm birth
• Lower birth weight (LBW)
• Small for gestational age (SGA)
• Depression and anxiety often comorbid
• Increased effort to distinguish impact of illness from medication exposure on obstetrical and neonatal outcome
Relative Impact of AD Exposure vs. Depression in Obstetrical and Neonatal Outcome
Steer RA et al. J Clin Epidemiol. 1992 Wisner Am J Psychiatry 2009 Yonkers KA, et al. Obstet Gynecol. 2009 Warburton et al 2010
10/26/2018
4
A Meta‐analysis of Depression During Pregnancy and the Risk of Preterm Birth, Low Birth Weight, and Intrauterine Growth Restriction
Grote et al. Arch Gen Psychiatry. 2010
Rifkin‐Graboi et al. Biol Psychiatry 2013.
Figure 1. The top and bottom rows, respectively, show the brain using the color map of diffusion tensor imaging and T2‐weighted magnetic resonance imaging from one infant of our sample. The axial, coronal, and sagittal slices are respectively illustrated from left to right. The red contour indicates the amygdala on diffusion tensor imaging and T2‐weighted magnetic resonance imaging.
Untreated Psychiatric Disorders During Pregnancy: Effects on Fetal Brain and HPA‐Axis
10/26/2018
5
13
What is the Safest Antidepressant for Women of Childbearing Age?
13
Phasing Out: FDA Pregnancy Categories
• Category A: – Well controlled studies in human pregnancy show no increased risk to
the fetus
• Category B: – Animal studies show no increased risk to the fetus OR
– Animal studies show an increased risk to the fetus but well controlled human studies do not.
• Category C:
– Animal studies show an increased risk to the fetus and there are no well controlled studies in human pregnancy OR
– There aren’t any animal studies or well controlled human studies.
http://womensmentalhealth.org/posts/fda‐finalizes‐guidelines‐pregnancy‐lactation‐labeling‐information/
10/26/2018
6
16
SSRI Use During Pregnancy
• Recent findings and more data inform the pharmacologic treatment of depression during pregnancy
– Consistent conclusions that the absolute risk of SSRI exposure in pregnancy is small1‐3
– Consistent pattern of malformations with SSRI exposure is lacking
– Case‐control studies reveal inconsistent data regarding teratogenic risk of individual SSRIs4‐9
Reproductive safety data on SSRIs exceed what is known about most other medicines used in
pregnancy
1 Louik C et al. N Engl J Med 2007; 2 Einarson TR, Einarson A. Pharmacoepidemiol Drug Saf 2005; 3 Einarson A, et al. Am J Psychiatry 2008; 4 Alwan S, et al. N Engl J Med 2007; 5 Greene MF. N Engl J Med 2007; 6 Hallberg P, Sjoblom V. J Clin Psychopharmacol 2005; 7Wogelius P, et al. Epidemiology 2006; 8 www.gsk.ca/english/docs‐pdf/PAXIL_PregnancyDHCPL_E‐V4.pdf Dear Healthcare Professional (3/17/08); 9 www.fda.gov/medwatch/safety/2005/Paxil_dearhcp_letter.pdf Dear Healthcare Professional (3/17/08); Grigoriadis et al. J Clin Psychiatry 2013.
• No evidence of increased risk for major malformations or cardiovascular malformations in children of pregnant women exposed to SSRIs
Cardiovascular Malformation and Fetal SSRI Exposure
Huybrechts et al. NEJM 2014.
10/26/2018
7
19
• Consistent data: Late trimester exposure to SSRIs is associated with transient irritability, agitation, jitteriness, and tachypnea (25‐30%)
• Overall studies do not adequately control for maternal mental health condition, adequate blinding of exposure in neonatal assessments
• Clinical implication: Should women be treated with antidepressants late in pregnancy and during labor and delivery (Warburton et al. 2010)
• Are any subgroups of newborns vulnerable to enduring symptoms beyond the first days of life ?
“Poor Neonatal Adaptation” and SSRI Use During Pregnancy
Levinson‐Castiel R, et al. Arch Pediatr Adolesc Med. 2006Chambers CD, et al. N Engl J Med. 2006Chambers, BMJ, 2009CWMH Blog, July 27 2005: http://womensmentalhealth.org/posts/neonatal‐symptoms‐after‐in‐utero‐exposure‐to‐ssris/
19
20Chambers CD, et al. N Engl J Med. 2006Hernández‐Díaz S, et al. Pediatrics. 2007
Risk for PPHN Associated with Late Trimester Exposure to Antidepressant
20
10/26/2018
8
22
Media Coverage of SSRI Use and Risk for Autism
Our response:
10/26/2018
9
25
What are the Long‐term Neurobehavioral Effects of Prenatal Exposure to an Antidepressant?
Recent review by Suri et al., J Clin Psychiatry 2014:• 13 prospective studies have assessed neurobehavioral infant outcome after in utero
antidepressant exposure
• N=721 children with antidepressant exposure and N=380 children without exposure
• The longest follow‐up has been 4 to 5 years
• The majority do not suggest major long term adverse effects of prenatal antidepressant exposure on infant/child neurobehavioral development; no significant differences in neurobehavior/development
• Generally encouraging but sample sizes have been small, and there are reports of possible subtle effects on gross motor function and language development, as well as the potential for longer‐term consequences following poor neonatal adaptation
• Most studies do not assess for nor quantify the severity of depressive symptoms in mothers across pregnancy
Antidepressants During Pregnancy: Long‐term Data
10/26/2018
10
JAMA Psychiatry; October 12, 2016
Invited Commentary, JAMA Psychiatry; October 12, 2016
10/26/2018
11
http://www.cnn.com/2016/10/12/health/antidepressants‐ssris‐pregnancy‐dyslexia/
32
• Treatment decisions are complex (maternal and fetal benefits and risks)
• Absolute quantification of risk associated with fetal exposure to medication or maternal disease is impossible
• No treatment decision is “perfect”
– Each treatment decision should try to optimize pregnancy outcomes for the mother and her child
– Consider the risks of untreated disease and the risks of medication treatment
Treatment of Depression During Pregnancy:Lessons Learned
Kallen Obstet Gynecol Int. 2012Palmsten and Hernandez‐Diaz Epidemiology 2012
• Psychotherapy: First‐line for mild to moderate MDD • Lifestyle components: Nutrition, weight management, prenatal care, childbirth education; treatment for substance abuse
• Document all exposures dating back to conception • Women trying to conceive who have histories of MDD:
–Encourage period of euthymia–Sustained remission: may consider tapering and discontinuing
–More recently depressed or with symptoms: consider remaining on medication, optimizing medication
• Pregnant women with severe MDD: Medication is first‐line • Pregnant women on antidepressants during pregnancy: take into account patient preferences, previous course of illness
• Medication selection should be based on known safety information
APA/ACOG Joint Recommendations
MDD, major depressive disorder.Yonkers KA et al. Obstet Gynecol. 2009;114(3):703‐713.
10/26/2018
12
• Depression during pregnancy is strongest predictor of postpartum depression
• There are known and unknown risks associated with AD use during pregnancy
• Adverse effects of depression in pregnancy on patient, infant and families
• Nothing trumps maternal euthymia
Summary of treatment considerations for women with MDD in pregnancy (cont.)
35
Treatment of Bipolar Disorder During Pregnancy
35
36
Cohen LS, et al. JAMA. 1994Steer RA, et al. J Clin Epidemiol. 1992 Orr ST, et al. Am J Prev Med. 1996 Suppes T, et al. Arch Gen Psychiatry. 1991 Faedda GL, et al. Arch Gen Psychiatry. 1993Baldessarini RJ, et al. Clin Psychiatry. 1996
• Commonly employed antimanic agents are either known teratogens or have sparse available reproductive safety data
• Risks of untreated psychiatric illness
• Risk of discontinuing maintenance psychotropic medications
Pharmacologic Treatment of Pregnant Women with Bipolar Disorder: Weighing Imperfect Options
10/26/2018
13
37
A NEW Research Study at the Massachusetts General Hospital
Center for Women’s Mental Health
To determine the safety of atypical antipsychotics in pregnancy for
women and their babies
Participation will involve 3 brief phone interviews over approximately 8
months
Call Toll‐Free:1‐866‐961‐2388
National Pregnancy Registry for Atypical Antipsychotics37
March 2016
• Primary aim: determine the risk of major malformations among infants exposed to second‐generation antipsychotics
• Prospectively enrolled 487 women
• The odds ratio for major malformations comparing exposed and unexposed infants was 1.25 (95% CI=0.13‐12.19)
• Current data indicate that second‐generation antipsychotics are not major teratogens
• Study is ongoing and continues to enroll women
• Prospective study
• As of April 23rd, 2018:
–1262 enrolled
–453 1st trimester exposures enrolled w/ evaluable data at time of analysis
–Risk ratio = 3.22 (0.92, 11.3)
–Quetiapine: 152 1st trimester exposures• Risk ratio = 0.90 (0.15, 5.46) AJP, (online, July2018)
• Preliminary conclusions: atypical antipsychotics are not major teratogens but more data are needed to narrow the confidence interval
Presented at ASCP, Cohen et al., 2018
National Pregnancy Registry for Atypical Antipsychotics: Preliminary Findings
10/26/2018
14
National Pregnancy Registry for Atypical Antipsychotics: Preliminary Findings
Presented at ASCP, Cohen et al., 2018; in press
• Primary aim: determine the risk of major malformations among infants exposed to atypical antipsychotics
• Examined Medicaid claim data from 1,341,715 pregnancies
• After adjustment for confounding, the risk ratio for congenital malformation in exposed versus unexposed infants was 1.05 (95% CI=0.96‐1.16)
• A slightly increased risk in overall and cardiac malformations was noted for risperidone
Lithium and Pregnancy
42
• Lithium Register of Babies 1970s• Ebstein’s Anomaly: 0.05 – 0.1% risk• Recent analysis from Medicaid database shows dose‐dependent increase in
risk of cardiovascular anomalies
10/26/2018
15
https://womensmentalhealth.org/posts/12021/?doing_wp_cron=1506358912.7760159969329833984375
• Overall risk of malformations elevated (6‐10%): neural tube defects, cardiac anomalies, cleft lip/palate, limb abnormalities
• Dose dependent: Risk for major malformations highest (25.2%) in women on high dose valproate (above 1450 mg/day)
• Higher rates associated with polytherapy• Neurodevelopmental sequelae: Increased risk of tautism spectrum disorders, behavioral problems, lower IQ
• Folic acid appears to ameliorate risk of autism spectrum disorders but not risk of malformations
• UK and France have banned use of valproic acid in certain population s of reproductive age women
Valproic Acid and Pregnancy
44
Recent study from EUROCAT
•107 of 1957 for carbamazepine = 5∙5%
•6 of 152 for topiramate = 3∙9%, oral clefts
•10 of 333 for oxcarbazepine = 3∙0%
•74 of 2514 for lamotrigine = 2∙9%
Inadequate data on the use of gabapentin, less than 350 exposures
Other Antiepileptic Drugs and Pregnancy
45
10/26/2018
16
Cognitive Function in 6 year olds Following Fetal Exposure to AED’s
Child IQ at 6 years, by exposure to maternal antiepileptic drug use and periconceptional folate
Meador, et al. Lancet Neurol. 2013
Mean (95% CIs) are shown for folate (solid lines) and no folate (dashed lines).
47
Treatment of Bipolar Illness During Pregnancy: What is a Reasonable Strategy?
Cohen LS, J Clin Psychiatry 2007 (suppl 9).
• Lithium and lamotrigine have well characterized reproductive safety profiles, low absolute risks
• Lithium may be the best characterized and reasonable alternative for women who require an anti‐manic agent but its use is declining
• Lamotrigine appears reasonable for the prevention of depressive episodes
• Atypical antipsychotics have growing body of data and do not at this time appear to be major teratogens
• More human pregnancy data available for older medications in the class
• May be reasonable to continue during pregnancy, particularly if patient has had good response, psychotic symptoms, is a lithium non‐responder, or atypical was critical in affording euthymia
48
• Polytherapy of bipolar disorder during pregnancy is the rule
• Frequency of use of atypical antipsychotics demands better data to inform use of these agents during pregnancy
• Absolute small risk may be acceptable versus risk of bipolar relapse during pregnancy and implications for puerperal relapse of the illness
Treatment of Bipolar Disorder during Pregnancy: Lessons Learned
10/26/2018
17
Postpartum Prophylaxis in Bipolar Women
0.0
0.2
0.4
0.6
0.8
1.0
0 2 4 6 8 10 12
Cumulative survival
Prophylaxis (N=14)
No prophylaxis (N=13)
Time (weeks)
Significant difference between groups(Peto‐Peto‐Wilcoxen 2 = 6.966, df = 1, p<0.01)
Cohen LS, Sichel DA, et al. Am J Psychiatry. 1995.
50
Postpartum Depression (PPD)
• 10‐15% of women experience PPD after delivery
• Similar to non‐puerperal major depression
• Most common complication in modern obstetrics
• Impairment of functioning
Postpartum Depression:Non‐Pharmacologic Strategies
• Maximize social supports
• Psychoeducation of patient and family members
• Group therapy and support groups
• Interpersonal therapy (IPT)
• Cognitive‐behavioral therapy (CBT) – Similar results: fluoxetine vs. 6 sessions CBT
Cohen et al. Psychiatr Clin North Am. 2010; Perlstein et al. Am J Obstet Gynecol 2009; Appleby et al., 1997.
10/26/2018
18
Study Design and Size Medication studied, result
Appleby et al., 1997 Placebo-controlled, N=87 CBT studied in same trial
Fluoxetine - superior to placebo
Yonkers et al, 2008 placebo controlled, N=70 Paroxetine - not superior to placebo)
Wisner et al., 2006 RCT, Setraline vs. Nortriptyline, N=109 Sertraline vs. Nortriptyline - no significant difference
Hantsoo et al., 2013 Placebo-controlled RCT, N=36 Setraline- superior to placebo
Bloch et al., 2012 N=40, all received brief psychodynamic therapy, RCT to sertraline or placebo
Both groups improved – no significant difference for sertraline vs. placebo
Sharp et al., 2010 RCT, AD selected by general practitioner or counseling, N=254
Antidepressants- superior to placebo
Misri et al., 2012 Open trial, N=15 Citalopram – open study
Misri et al., 2004 N=35, all received parox, half randomized to CBT also
Paroxetine – no control group
Stowe et al., 1995 Open-label; N=21 Sertraline – open study
Cohen et al., 1997 Open-label; N=19 Venlafaxine- open study
Suri et al., 2001 Open-label; N=6 Fluvoxamine - open
Nonacs et al., 2005 Open-label; N=8 Bupropion- open
Antidepressant Trials for the Treatment of PPD
Screening for Postpartum Depression
PPD, Screening, and Large Scale Efforts
• Federal legislation includes provisions for postpartum depression
–Language on screening for PPD and increased funding for its treatment and research
• Multiple states have implemented universal screening or are in the process of implementing screening
• Political impetus to screen for PPD
10/26/2018
19
J Clin Psychiatry 2016
MGHPDS
MGH Perinatal Depression Scale
10/26/2018
20
J Clin Psychiatry 2016